Background: The Psoriasis Area and Severity Index (PASI) is the most frequently used clinical severity scale in clinical trials. Drug approval often depends on a 75%improvement in the baseline PASI score, also known a...Background: The Psoriasis Area and Severity Index (PASI) is the most frequently used clinical severity scale in clinical trials. Drug approval often depends on a 75%improvement in the baseline PASI score, also known as a PASI 75 or Delta PASI 75. This benchmark may be an overly stringent way to determine the success of psoriasis treatments as Delta PASIs appear to under-represent true clinical improvement. This discrepancy may relate to the way numerical values are assigned to the degree of body surface area (BSA) involvement. Objectives: To assesswhether altering the BSA component of the PASI formula so that it is weighted more heavily will result in a calculated change in psoriasis severity that more closely reflects patient assessment of improvement. Models developed included the Psoriasis Log-based Area and Severity Index (PLASI), which assigns values to the BSA score based on a linear scale using logarithms to define the intervals, and the Psoriasis Exact Area and Severity Index (PEASI), which uses the actual BSA as the multiplicative factor in the area score. Methods: Data were abstracted retrospectively fromtwo clinical trials involving psoriasis treatments that used the PASI. The same trained psoriasis graders were involved in both trials. In these trials, baseline and end-point PASI worksheets were completed that included the actual clinician-estimated BSA involvement (0-100%) for each of the four areas (head, upper extremities, trunk and lower extremities). In one of the trials, patients were asked to assess the percentage improvement in their psoriasis at the end of the treatment window. PASIs and Delta PASIs were recalculated based on the newmodels and all scoring systemswere validated by analysing their relationship to patients’self-assessments. Results: Clinical improvements under the new grading systems translated into greater percentage changes than calculated using the Delta PASI formula. Specifically, the Delta PASI 50 translated to a Delta PLASI 57.2 and Delta PEASI 61.1; Delta PASI 75 was equivalent to Delta PLASI 85.7 and Delta PEASI 91.7. Importantly,Delta PASI tended to be systematically lower than patients’self-assessment, while Delta PLASI and Delta PEASI better matched patients’self-assessments using a best-fit model. Conclusions: These results suggest that the Delta PASI underestimates percentage improvement when compared with measures of patient’s self-assessment, while Delta PLASI and Delta PEASI correlate better. Prospective studies will have to be performed to confirm these relationships, but weighting BSA more heavily in the severity score may result in a more accurate reflection of clinical status.展开更多
目的:观察中西医结合治疗寻常型银屑病(psoriasis vulgaris)的临床疗效。方法:对本院2009年至2011年期间收治的286例寻常型银屑病患者,结合实际情况分别采用西医治疗(对照组196例)和中西医结合治疗(实验组90例)。统计分析两组银屑病皮...目的:观察中西医结合治疗寻常型银屑病(psoriasis vulgaris)的临床疗效。方法:对本院2009年至2011年期间收治的286例寻常型银屑病患者,结合实际情况分别采用西医治疗(对照组196例)和中西医结合治疗(实验组90例)。统计分析两组银屑病皮损面积和严重度指数(psoriasis area and severity index,PASI)变化及疗效。结果:PASI统计结果显示,在治疗前,对照组与实验组的PASI比较无显著性差异(P>0.05);治疗后,实验组明显低于对照组,有显著性差异(P<0.05)。疗效统计结果显示,实验组痊愈率明显高于对照组,有显著性差异(P<0.05)。结论:中西医结合治疗银屑病有更好的临床疗效。展开更多
目的:探讨白介素(IL)-18及IL-27在寻常性银屑病(PV)发病机制中的作用。方法:采用实时荧光定量聚合酶链式反应(PCR)检测54例PV患者和40例健康对照组外周血中IL-18及IL-27 m RNA的表达,分析42例PV患者应用白芍总苷(TGP)治疗4周后及23例患...目的:探讨白介素(IL)-18及IL-27在寻常性银屑病(PV)发病机制中的作用。方法:采用实时荧光定量聚合酶链式反应(PCR)检测54例PV患者和40例健康对照组外周血中IL-18及IL-27 m RNA的表达,分析42例PV患者应用白芍总苷(TGP)治疗4周后及23例患者治疗8周后外周血中IL-18及IL-27 m RNA的表达水平,并对患者进行银屑病皮损面积和严重程度指数(PASI)评分。结果:PV患者外周血中IL-18和IL-27 m RNA的表达水平明显高于健康对照组(P<0.01)。IL-18与IL-27的ΔCt值呈正相关(r=0.706,P<0.05)。PASI评分与IL-18 m RNA表达呈正相关(r=0.613,P<0.05),与IL-27 m RNA的表达无明显相关性(P>0.05);经TGP治疗4周后,患者外周血中IL-18和IL-27 m RNA的表达及PASI评分均明显降低(P<0.05)。与治疗4周后比较,治疗8周后患者IL-18 m RNA的表达及PASI评分也明显降低(P<0.05);而IL-27 m RNA的表达差异无统计学意义(P>0.05),但PASI评分降低(P<0.05)。结论:IL-18及IL-27可能与PV发病有关。展开更多
目的我国银屑病患者数量庞大,约650万例,且患病率呈现增长趋势,但目前仍缺乏对我国银屑病患者多中心的大数据研究。本研究分析了6093例银屑病患者的发病特点及其临床特征,将有助于加深对我国银屑病特点的认识,改进治疗方案和患者管理措...目的我国银屑病患者数量庞大,约650万例,且患病率呈现增长趋势,但目前仍缺乏对我国银屑病患者多中心的大数据研究。本研究分析了6093例银屑病患者的发病特点及其临床特征,将有助于加深对我国银屑病特点的认识,改进治疗方案和患者管理措施。方法本研究依托银屑病规范化诊疗中心临床大数据采集平台,截至2020年12月,数据采自129家医院,总样本量6093例。本研究回顾分析了中国银屑病患者人口学特征、遗传特征、个人习惯、环境因素、疾病特征以及治疗现状。结果本研究共纳入男性3936例,女性2157例,年龄1~95岁。男女患者的年龄分布规律相似。对19岁及以上年龄患者进行体质量指数(body mass index,BMI)统计分析,整体患者的BMI均数为(23.66±2.92)kg/m^(2),男性患者的BMI均数略高于女性患者。7~18岁、19~44岁年龄段患者平均病程分别为1.99年和6.93年,45~60岁、61岁及以上2个年龄段患者的病程均超过10年。在19岁及以上患者中,不吸烟人数与吸烟人数之比约为7∶3。临床表现以斑块状银屑病占比最高(78.22%),其次是点滴状银屑病,占比18.70%;关节病型(3.69%)、脓疱型(局限性加泛发性,3.51%)和红皮病型(2.96%)发生率较低。从银屑病皮损面积和严重程度指数评分来看,中重度患者占比达75%,比例也随年龄增长而升高。超过85.0%的患者表现为多重部位皮损,皮损发生部位按占比由高至低依次为下肢、头皮、上肢、背部、胸部、手、足、面、颈、生殖器。接近16.79%的患者有伴发疾病,并且随年龄增长比例升高。16.05%的银屑病患者有明确的家族史。绝大多数患者(88.29%)最迫切的治疗需求是快速修复皮损,其次是降低治疗费用(45.31%)、明显减少瘙痒(43.55%)、减少就医次数或缩短治疗时间(40.48%)、减少药物不良反应(37.50%)。对患者在2020年的治疗情况进行分析,接受过局部治疗、系统药物(非生物制剂)及光疗、生物制剂治疗的比例分别为73.56%、48.00%、7.10%,但对治疗效果非常满意或满意的比例仅为34.16%。结论银屑病作为一种慢性系统性疾病,在中国有庞大的患者人群,本研究患者数据显示,我国银屑病患者具有病程长、疾病严重程度较高等临床特点。然而,目前我国患者对银屑病危害认知不足,就诊习惯不佳,且对治疗满意度也不高。因此,建设银屑病规范化诊疗中心十分必要。展开更多
目的:观察九味化斑方治疗寻常型银屑病的临床疗效。方法:筛选符合入组条件的寻常型银屑病患者40例,采用九味化斑方治疗,平均治疗时间(86.08±42.55)d,通过银屑病皮损面积和严重程度指数(Psoriasis Area and Severity Index,PASI)进...目的:观察九味化斑方治疗寻常型银屑病的临床疗效。方法:筛选符合入组条件的寻常型银屑病患者40例,采用九味化斑方治疗,平均治疗时间(86.08±42.55)d,通过银屑病皮损面积和严重程度指数(Psoriasis Area and Severity Index,PASI)进行疗效评价。结果:40例患者治疗前后PASI评分的改善有显著差异(P<0.01),40例患者中痊愈18例,显效13例,有效5例,无效4例,总有效率90%(36/40)。结论九味化斑方能显著改善寻常型银屑病患者的皮损面积和严重程度,疗效显著。展开更多
文摘Background: The Psoriasis Area and Severity Index (PASI) is the most frequently used clinical severity scale in clinical trials. Drug approval often depends on a 75%improvement in the baseline PASI score, also known as a PASI 75 or Delta PASI 75. This benchmark may be an overly stringent way to determine the success of psoriasis treatments as Delta PASIs appear to under-represent true clinical improvement. This discrepancy may relate to the way numerical values are assigned to the degree of body surface area (BSA) involvement. Objectives: To assesswhether altering the BSA component of the PASI formula so that it is weighted more heavily will result in a calculated change in psoriasis severity that more closely reflects patient assessment of improvement. Models developed included the Psoriasis Log-based Area and Severity Index (PLASI), which assigns values to the BSA score based on a linear scale using logarithms to define the intervals, and the Psoriasis Exact Area and Severity Index (PEASI), which uses the actual BSA as the multiplicative factor in the area score. Methods: Data were abstracted retrospectively fromtwo clinical trials involving psoriasis treatments that used the PASI. The same trained psoriasis graders were involved in both trials. In these trials, baseline and end-point PASI worksheets were completed that included the actual clinician-estimated BSA involvement (0-100%) for each of the four areas (head, upper extremities, trunk and lower extremities). In one of the trials, patients were asked to assess the percentage improvement in their psoriasis at the end of the treatment window. PASIs and Delta PASIs were recalculated based on the newmodels and all scoring systemswere validated by analysing their relationship to patients’self-assessments. Results: Clinical improvements under the new grading systems translated into greater percentage changes than calculated using the Delta PASI formula. Specifically, the Delta PASI 50 translated to a Delta PLASI 57.2 and Delta PEASI 61.1; Delta PASI 75 was equivalent to Delta PLASI 85.7 and Delta PEASI 91.7. Importantly,Delta PASI tended to be systematically lower than patients’self-assessment, while Delta PLASI and Delta PEASI better matched patients’self-assessments using a best-fit model. Conclusions: These results suggest that the Delta PASI underestimates percentage improvement when compared with measures of patient’s self-assessment, while Delta PLASI and Delta PEASI correlate better. Prospective studies will have to be performed to confirm these relationships, but weighting BSA more heavily in the severity score may result in a more accurate reflection of clinical status.
文摘目的:观察中西医结合治疗寻常型银屑病(psoriasis vulgaris)的临床疗效。方法:对本院2009年至2011年期间收治的286例寻常型银屑病患者,结合实际情况分别采用西医治疗(对照组196例)和中西医结合治疗(实验组90例)。统计分析两组银屑病皮损面积和严重度指数(psoriasis area and severity index,PASI)变化及疗效。结果:PASI统计结果显示,在治疗前,对照组与实验组的PASI比较无显著性差异(P>0.05);治疗后,实验组明显低于对照组,有显著性差异(P<0.05)。疗效统计结果显示,实验组痊愈率明显高于对照组,有显著性差异(P<0.05)。结论:中西医结合治疗银屑病有更好的临床疗效。
文摘目的:探讨白介素(IL)-18及IL-27在寻常性银屑病(PV)发病机制中的作用。方法:采用实时荧光定量聚合酶链式反应(PCR)检测54例PV患者和40例健康对照组外周血中IL-18及IL-27 m RNA的表达,分析42例PV患者应用白芍总苷(TGP)治疗4周后及23例患者治疗8周后外周血中IL-18及IL-27 m RNA的表达水平,并对患者进行银屑病皮损面积和严重程度指数(PASI)评分。结果:PV患者外周血中IL-18和IL-27 m RNA的表达水平明显高于健康对照组(P<0.01)。IL-18与IL-27的ΔCt值呈正相关(r=0.706,P<0.05)。PASI评分与IL-18 m RNA表达呈正相关(r=0.613,P<0.05),与IL-27 m RNA的表达无明显相关性(P>0.05);经TGP治疗4周后,患者外周血中IL-18和IL-27 m RNA的表达及PASI评分均明显降低(P<0.05)。与治疗4周后比较,治疗8周后患者IL-18 m RNA的表达及PASI评分也明显降低(P<0.05);而IL-27 m RNA的表达差异无统计学意义(P>0.05),但PASI评分降低(P<0.05)。结论:IL-18及IL-27可能与PV发病有关。
文摘目的我国银屑病患者数量庞大,约650万例,且患病率呈现增长趋势,但目前仍缺乏对我国银屑病患者多中心的大数据研究。本研究分析了6093例银屑病患者的发病特点及其临床特征,将有助于加深对我国银屑病特点的认识,改进治疗方案和患者管理措施。方法本研究依托银屑病规范化诊疗中心临床大数据采集平台,截至2020年12月,数据采自129家医院,总样本量6093例。本研究回顾分析了中国银屑病患者人口学特征、遗传特征、个人习惯、环境因素、疾病特征以及治疗现状。结果本研究共纳入男性3936例,女性2157例,年龄1~95岁。男女患者的年龄分布规律相似。对19岁及以上年龄患者进行体质量指数(body mass index,BMI)统计分析,整体患者的BMI均数为(23.66±2.92)kg/m^(2),男性患者的BMI均数略高于女性患者。7~18岁、19~44岁年龄段患者平均病程分别为1.99年和6.93年,45~60岁、61岁及以上2个年龄段患者的病程均超过10年。在19岁及以上患者中,不吸烟人数与吸烟人数之比约为7∶3。临床表现以斑块状银屑病占比最高(78.22%),其次是点滴状银屑病,占比18.70%;关节病型(3.69%)、脓疱型(局限性加泛发性,3.51%)和红皮病型(2.96%)发生率较低。从银屑病皮损面积和严重程度指数评分来看,中重度患者占比达75%,比例也随年龄增长而升高。超过85.0%的患者表现为多重部位皮损,皮损发生部位按占比由高至低依次为下肢、头皮、上肢、背部、胸部、手、足、面、颈、生殖器。接近16.79%的患者有伴发疾病,并且随年龄增长比例升高。16.05%的银屑病患者有明确的家族史。绝大多数患者(88.29%)最迫切的治疗需求是快速修复皮损,其次是降低治疗费用(45.31%)、明显减少瘙痒(43.55%)、减少就医次数或缩短治疗时间(40.48%)、减少药物不良反应(37.50%)。对患者在2020年的治疗情况进行分析,接受过局部治疗、系统药物(非生物制剂)及光疗、生物制剂治疗的比例分别为73.56%、48.00%、7.10%,但对治疗效果非常满意或满意的比例仅为34.16%。结论银屑病作为一种慢性系统性疾病,在中国有庞大的患者人群,本研究患者数据显示,我国银屑病患者具有病程长、疾病严重程度较高等临床特点。然而,目前我国患者对银屑病危害认知不足,就诊习惯不佳,且对治疗满意度也不高。因此,建设银屑病规范化诊疗中心十分必要。
文摘目的:观察九味化斑方治疗寻常型银屑病的临床疗效。方法:筛选符合入组条件的寻常型银屑病患者40例,采用九味化斑方治疗,平均治疗时间(86.08±42.55)d,通过银屑病皮损面积和严重程度指数(Psoriasis Area and Severity Index,PASI)进行疗效评价。结果:40例患者治疗前后PASI评分的改善有显著差异(P<0.01),40例患者中痊愈18例,显效13例,有效5例,无效4例,总有效率90%(36/40)。结论九味化斑方能显著改善寻常型银屑病患者的皮损面积和严重程度,疗效显著。
